Targeting neddylation pathways to inactivate cullin-RING ligases for anticancer therapy

Antioxidants and Redox Signaling

Volumn 21, Issue 17, 2014, Pages 2383-2400

  Zhao, Yongchao ^a   Morgan, Meredith A ^a   Sun, Yi ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CARBOPLATIN; CELL PROTEIN; CULLIN; CULLIN RING LIGASE; DOCETAXEL; GEMCITABINE; PACLITAXEL; PEVONEDISTAT; PROTEIN MDM2; PROTEIN P53; PROTEIN P73; REACTIVE OXYGEN METABOLITE; RIBOSOME PROTEIN; UBIQUITIN PROTEIN LIGASE E3; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; LIGASE; NEDD8 PROTEIN, HUMAN; UBIQUITIN;

APOPTOSIS; AUTOPHAGY; BIOLOGICAL PHENOMENA AND FUNCTIONS CONCERNING THE ENTIRE ORGANISM; CANCER THERAPY; CARCINOGENESIS; CELL AGING; CELL CYCLE PROGRESSION; CHEMORADIOTHERAPY; CHEMOSENSITIZATION; EVOLUTION; HOMEOSTASIS; HUMAN; NEDDYLATION; NONHUMAN; PROTEIN CONFORMATION; RADIOSENSITIZATION; REGULATORY MECHANISM; REVIEW; RING FINGER MOTIF; SIGNAL TRANSDUCTION; TUMOR GROWTH; UBIQUITINATION; DRUG DESIGN; METABOLISM; NEOPLASMS;

ANTINEOPLASTIC AGENTS; CULLIN PROTEINS; DRUG DESIGN; HUMANS; LIGASES; NEOPLASMS; UBIQUITINS;

EID: 84904261166     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5795     Document Type: Review

References (170)

1. Abbas T, Sivaprasad U, Terai K, Amador V, Pagano M, and Dutta A. PCNA-dependent regulation of p21 ubiquitylation and degradation via the CRL4Cdt2 ubiquitin ligase complex. Genes Dev 22: 2496-2506, 2008.
2. Abdelmohsen K and Gorospe M. Posttranscriptional regulation of cancer traits by HuR. Wiley Interdiscip Rev RNA 1: 214-229, 2010.
3. Abida WM, Nikolaev A, Zhao W, Zhang W, and Gu W. FBXO11 promotes the neddylation of p53 and inhibits its transcriptional activity. J BiolChem282: 1797-1804, 2007.
4. Artavanis-Tsakonas K, Misaghi S, Comeaux CA, Catic A, Spooner E, Duraisingh MT, and Ploegh HL. Identification by functional proteomics of a deubiquitinating/deNeddylating enzyme in Plasmodium falciparum. Mol Microbiol 61: 1187-1195, 2006.
5. Bech-Otschir D, Seeger M, and Dubiel W. The COP9 signalosome: at the interface between signal transduction and ubiquitin-dependent proteolysis. J Cell Sci 115: 467-473, 2002.
6. Bjorklund M, Taipale M, Varjosalo M, Saharinen J, Lahdenpera J, and Taipale J. Identification of pathways regulating cell size and cell-cycle progression by RNAi. Nature 439: 1009-1013, 2006.
7. Blank JL, Liu XJ, Cosmopoulos K, Bouck DC, Garcia K, Bernard H, Tayber O, Hather G, Liu R, Narayanan U, Milhollen MA, and Lightcap ES. Novel DNA damage checkpoints mediating cell death induced by the NEDD8-activating enzyme inhibitor MLN4924. Cancer Res 73: 225-234, 2013.
8. Bohnsack RN and Haas AL. Conservation in the mechanism of Nedd8 activation by the human AppBp1-Uba3 heterodimer. J Biol Chem 278: 26823-26830, 2003.
9. Broemer M, Tenev T, Rigbolt KTG, Hempel S, Blagoev B, Silke J, Ditzel M, and Meier P. Systematic in vivo rnai analysis identifies IAPs as NEDD8-E3 ligases. Mol Cell 40: 810-822, 2010.
10. Brownell JE, Sintchak MD, Gavin JM, Liao H, Bruzzese FJ, Bump NJ, Soucy TA, Milhollen MA, Yang X, Burkhardt AL, Ma J, Loke HK, Lingaraj T, Wu D, Hamman KB, Spelman JJ, Cullis CA, Langston SP, Vyskocil S, Sells TB, Mallender WD, Visiers I, Li P, Claiborne CF, Rolfe M, Bolen JB, and Dick LR. Substrate-assisted inhibition of ubiquitin-like protein-activating enzymes: the NEDD8 E1 inhibitor MLN4924 forms a NEDD8-AMP mimetic in situ. Mol Cell 37: 102-111, 2010.
11. Carter SA and Vousden KH. p53-Ubl fusions as models of ubiquitination, sumoylation and neddylation of p53. Cell Cycle 7: 2519-2528, 2008.
12. Chairatvit K and Ngamkitidechakul C. Control of cell proliferation via elevated NEDD8 conjugation in oral squamous cell carcinoma. Mol Cell Biochem 306: 163-169, 2007.
13. Choo YS, Vogler G, Wang D, Kalvakuri S, Iliuk A, Tao WA, Bodmer R, and Zhang Z. Regulation of parkin and PINK1 by neddylation. Hum Mol Genet 21: 2514-2523, 2012.
14. Chowdhry S, Zhang Y, McMahon M, Sutherland C, Cuadrado A, and Hayes JD. Nrf2 is controlled by two distinct beta-TrCP recognition motifs in its Neh6 domain, one of which can be modulated by GSK-3 activity. Oncogene 32: 3765-3781, 2013.
15. Ciechanover A. The ubiquitin-proteasome pathway: on protein death and cell life. EMBO J 17: 7151-7160, 1998.
16. Ciechanover A. The ubiquitin proteolytic system and pathogenesis of human diseases: a novel platform for mechanism-based drug targeting. Biochem Soc Trans 31: 474-481, 2003.
17. Ciechanover A and Iwai K. The ubiquitin system: from basic mechanisms to the patient bed. IUBMB Life 56: 193-201, 2004.
18. Cope GA and Deshaies RJ. COP9 signalosome: a multifunctional regulator of SCF and other cullin-based ubiquitin ligases. Cell 114: 663-671, 2003.
19. Cox J and Mann M. Quantitative, high-resolution proteomics for data-driven systems biology. Annu Rev Biochem 80: 273-299, 2011.
20. de Oca Luna RM, Wagner DS, and Lozano G. Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. Nature 378: 203-206, 1995.
21. Deshaies RJ, Emberley ED, and Saha A. Control of cullin-RING ubiquitin ligase activity by Nedd8. In: Conjugation and Deconjugation of Ubiquitin Family Modifiers: Subcellular Biochemistry, edited by Groettrup M. New York: Springer, 2010, pp. 41-56.
22. Deshaies RJ and Joazeiro CAP. RING Domain E3 Ubiquitin Ligases. Annu Rev Biochem 78: 399-434, 2009.
23. Dharmasiri S, Dharmasiri N, Hellmann H, and Estelle M. The RUB/Nedd8 conjugation pathway is required for early development in Arabidopsis. EMBO J 22: 1762-1770, 2003.
24. Dil Kuazi A, Kito K, Abe Y, Shin R-W, Kamitani T, and Ueda N. NEDD8 protein is involved in ubiquitinated inclusion bodies. J Pathol 199: 259-266, 2003.
25. Dohmesen C, Koeppel M, and Dobbelstein M. Specific inhibition of Mdm2-mediated neddylation by Tip60. Cell Cycle 7: 222-231, 2008.
26. Duan H, Wang Y, Aviram M, Swaroop M, Loo JA, Bian J, Tian Y, Mueller T, Bisgaier CL, and Sun Y. SAG, a novel zinc RING finger protein that protects cells from apoptosis induced by redox agents. Mol Cell Biol 19: 3145-3155, 1999.
27. Duan S, Skaar Jeffrey R, Kuchay S, Toschi A, Kanarek N, Ben-Neriah Y, and Pagano M. mTOR generates an auto-amplification loop by triggering the bTrCP-and CK1a-dependent degradation of DEPTOR. Mol Cell 44: 317-324, 2011.
28. Duda DM, Borg LA, Scott DC, Hunt HW, Hammel M, and Schulman BA. Structural insights into NEDD8 activation of Cullin-RING ligases: conformational control of conjugation. Cell 134: 995-1006, 2008.
29. Emanuele Michael J, Elia Andrew EH, Xu Q, Thoma Claudio R, Izhar L, Leng Y, Guo A, Chen Y-N, Rush J, Hsu Paul W-C, Yen H-Chi S, and Elledge Stephen J. Global identification of modular cullin-RING ligase substrates. Cell 147: 459-474, 2011.
30. Embade N, Fernández-Ramos D, Varela-Rey M, Beraza N, Sini M, de Juan VG, Woodhoo A, Martnez-López N, Rodŕguez-Iruretagoyena B, Bustamante FJ, de la Hoz AB, Carracedo A, Xirodimas DP, Rodŕguez MS, Lu SC, Mato JM, and Martnez-Chantar ML. Murine double minute 2 regulates Hu antigen R stability in human liver and colon cancer through NEDDylation. Hepatology 55: 1237-1248, 2012.
31. Ferro A, Carvalho AL, Teixeira-Castro A, Almeida C, Tomé RJ, Cortes L, Rodrigues A-J, Logarinho E, Sequeiros J, Macedo-Ribeiro S, and Maciel P. NEDD8: a new ataxin-3 interactor. Biochim Biophys Acta 1773: 1619-1627, 2007.
32. Finkel T. Signal transduction by reactive oxygen species. J Cell Biol 194: 7-15, 2011.
33. Gan-Erdene T, Nagamalleswari K, Yin L, Wu K, Pan ZQ, and Wilkinson KD. Identification and characterization of DEN1, a deneddylase of the ULP family. J Biol Chem 278: 28892-28900, 2003.
34. Gao D, Inuzuka H, Tan M-Kwang M, Fukushima H, Locasale Jason W, Liu P, Wan L, Zhai B, Chin YR, Shaik S, Lyssiotis Costas A, Gygi Steven P, Toker A, Cantley Lewis C, Asara John M, Harper JW, and Wei W. mTOR drives its own activation via SCFbTrCP-dependent degradation of the mTOR inhibitor DEPTOR. Mol Cell 44: 290-303, 2011.
35. Gao F, Cheng J, Shi T, and Yeh ETH. Neddylation of a breast cancer-associated protein recruits a class III histone deacetylase that represses NF[kappa]B-dependent transcription. Nat Cell Biol 8: 1171-1177, 2006.
36. Goldenberg SJ, Cascio TC, Shumway SD, Garbutt KC, Liu JD, Xiong Y, and Zheng N. Structure of the Cand1-Cul1-Roc1 complex reveals regulatory mechanisms for the assembly of the multisubunit cullin-dependent ubiquitin ligases. Cell 119: 517-528, 2004.
37. Gong L, Kamitani T, Millas S, and Yeh ETH. Identification of a novel isopeptidase with dual specificity for ubiquitin-and NEDD8-conjugated proteins. J Biol Chem 275: 14212-14216, 2000.
38. Handeli S and Weintraub H. The ts41 mutation in Chinese hamster cells leads to successive S phases in the absence of intervening G2, M, and G1. Cell 71: 599-611, 1992.
39. Hayes JD and McMahon M. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer. Trends Biochem Sci 34: 176-188, 2009.
40. Hemelaar J, Borodovsky A, Kessler BM, Reverter D, Cook J, Kolli N, Gan-Erdene T, Wilkinson KD, Gill G, Lima CD, Ploegh HL, and Ovaa H. Specific and covalent targeting of conjugating and deconjugating enzymes of ubiquitin-like proteins. Mol Cell Biol 24: 84-95, 2004.
41. Hershko A and Ciechanover A. The ubiquitin system. Annu Rev Biochem 67: 425-479, 1998.
42. Hu J, McCall CM, Ohta T, and Xiong Y. Targeted ubiquitination of CDT1 by the DDB1-CUL4A-ROC1 ligase in response to DNA damage. Nat Cell Biol 6: 1003-1009, 2004.
43. Huang DT, Ayrault O, Hunt HW, Taherbhoy AM, Duda DM, Scott DC, Borg LA, Neale G, Murray PJ, Roussel MF, and Schulman BA. E2-RING Expansion of the NEDD8 cascade confers specificity to cullin modification. Mol Cell 33: 483-495, 2009.
44. Itoh K, Mimura J, and Yamamoto M. Discovery of the negative regulator of Nrf2, Keap1: a historical overview. Antioxid Redox Signal 13: 1665-1678, 2010.
45. Ivan M, Kondo K, Yang HF, Kim W, Valiando J, Ohh M, Salic A, Asara JM, Lane WS, and Kaelin WG. HIF alpha targeted for VHL-mediated destruction by proline hydroxylation: implications for O-2 sensing. Science 292: 464-468, 2001.
46. Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ, von Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH, Pugh CW, and Ratcliffe PJ. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O-2-regulated prolyl hydroxylation. Science 292: 468-472, 2001.
47. Jazaeri AA, Shibata E, Park J, Bryant JL, Conaway MR, Modesitt SC, Smith PG, Milhollen MA, Berger AJ, and Dutta A. Overcoming platinum resistance in preclinical models of ovarian cancer using the neddylation inhibitor MLN4924. Mol Cancer Ther 12: 1958-1967, 2013.
48. Jia L, Li H, and Sun Y. Induction of p21-dependent senescence by an NAE inhibitor, MLN4924, as a mechanism of growth suppression. Neoplasia 13: 561-569, 2011.
49. Jia L and Sun Y. SCF E3 ubiquitin ligases as anticancer targets. Curr Cancer Drug Targets 11: 347-356, 2011.
50. Jia L, Yang J, Hao X, Zheng M, He H, Xiong X, Xu L, and Sun Y. Validation of SAG/RBX2/ROC2 E3 ubiquitin ligase as an anticancer and radiosensitizing target. Clin Cancer Res 16: 814-824, 2010.
51. Jin H-s, Liao L, Park Y, and Liu Y-C. Neddylation pathway regulates T-cell function by targeting an adaptor protein Shc and a protein kinase Erk signaling. Proc Natl Acad Sci USA 110: 624-629, 2013.
52. Johnston SC, Larsen CN, Cook WJ, Wilkinson KD, and Hill CP. Crystal structure of a deubiquitinating enzyme (human UCH-L3) at 1.8A resolution. EMBO J 16: 3787-3796, 1997.
53. Jones D and Candido EPM. The NED-8 conjugating system in Caenorhabditis elegans is required for embryogenesis and terminal differentiation of the hypodermis. Dev Biol 226: 152-165, 2000.
54. Jones S, Zhang X, Parsons DW, Lin JC, Leary RJ, Angenendt P, Mankoo P, Carter H, Kamiyama H, Jimeno A, Hong SM, Fu B, Lin MT, Calhoun ES, Kamiyama M, Walter K, Nikolskaya T, Nikolsky Y, Hartigan J, Smith DR, Hidalgo M, Leach SD, Klein AP, Jaffee EM, Goggins M, Maitra A, Iacobuzio-Donahue C, Eshleman JR, Kern SE, Hruban RH, Karchin R, Papadopoulos N, Parmigiani G, Vogelstein B, Velculescu VE, and Kinzler KW. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321: 1801-1806, 2008.
55. Jones SN, Roe AE, Donehower LA, and Bradley A. Rescue of embryonic lethality in Mdm2-deficient mice by absence of p53. Nature 378: 206-208, 1995.
56. Kamitani T, Kito K, Nguyen HP, and Yeh ETH. Characterization of NEDD8, a developmentally downregulated ubiquitin-like protein. J Biol Chem 272: 28557-28562, 1997.
57. Kamura T, Conrad MN, Yan Q, Conaway RC, and Conaway JW. The Rbx1 subunit of SCF and VHL E3 ubiquitin ligase activates Rub1 modification of cullins Cdc53 and Cul2. Genes Dev 13: 2928-2933, 1999.
58. Kee Y, Huang M, Chang S, Moreau LA, Park E, Smith PG, and D'Andrea AD. Inhibition of the Nedd8 system sensitizes cells to DNA interstrand cross-linking agents. Mol Cancer Res 10: 369-377, 2012.
59. Kensler TW, Wakabayashi N, and Biswal S. Cell survival responses to environmental stresses via the Keap1-Nrf2-ARE pathway. Annu Rev Pharmacol Toxicol 47: 89-116, 2007.
60. Kim W, Bennett EJ, Huttlin EL, Guo A, Li J, Possemato A, Sowa ME, Rad R, Rush J, Comb MJ, Harper JW, and Gygi SP. Systematic and quantitative assessment of the ubiquitin-modified proteome. Mol Cell 44: 325-340, 2011.
61. Kim Y, Starostina NG, and Kipreos ET. The CRL4Cdt2 ubiquitin ligase targets the degradation of p21Cip1 to control replication licensing. Genes Dev 22: 2507-2519, 2008.
62. Kumar A, Wu H, Collier-Hyams LS, Hansen JM, Li T, Yamoah K, Pan ZQ, Jones DP, and Neish AS. Commensal bacteria modulate cullin-dependent signaling via generation of reactive oxygen species. EMBO J 26: 4457-4466, 2007.
63. Kumar A, Wu H, Collier-Hyams LS, Kwon YM, Hanson JM, and Neish AS. The bacterial fermentation product butyrate influences epithelial signaling via reactive oxygen species-mediated changes in cullin-1 neddylation. J Immunol 182: 538-546, 2009.
64. Kumar S, Tomooka Y, and Noda M. Identification of a set of genes with developmentally down-regulated expression in the mouse brain. Biochem Biophys Res Commun 185: 1155-1161, 1992.
65. Kumar S, Yoshida Y, and Noda M. Cloning of a cDNA which encodes a novel ubiquitin-like protein. Biochem Biophys Res Commun 195: 393-399, 1993.
66. Kurz T, Chou Y-C, Willems AR, Meyer-Schaller N, Hecht M-L, Tyers M, Peter M, and Sicheri F. Dcn1 functions as a scaffold-type E3 ligase for cullin neddylation. Mol Cell 29: 23-35, 2008.
67. Kurz T, Ozlu N, Rudolf F, O'Rourke SM, Luke B, Hofmann K, Hyman AA, Bowerman B, and Peter M. The conserved protein DCN-1/Dcn1p is required for cullin neddylation in C. elegans and S. cerevisiae. Nature 435: 1257-1261, 2005.
68. Kurz T, Pintard L, Willis JH, Hamill DR, Gönczy P, Peter M, and Bowerman B. Cytoskeletal regulation by the Nedd8 ubiquitin-like protein modification pathway. Science 295: 1294-1298, 2002.
69. Lammer D, Mathias N, Laplaza JM, Jiang W, Liu Y, Callis J, Goebl M, and Estelle M. Modification of yeast Cdc53p by the ubiquitin-related protein Rub1p affects function of the SCFCdc4 complex. Genes Dev 12: 914-926, 1998.
70. Larance M, Kirkwood KJ, Xirodimas DP, Lundberg E, Uhlen M, and Lamond AI. Characterization of MRFAP1 turnover and interactions downstream of the NEDD8 pathway. Mol Cell Proteomics 11: M111.014407, 2012.
71. Larsen CN, Price JS, and Wilkinson KD. Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues. Biochemistry 35: 6735-6744, 1996.
72. Lee M-R, Lee D, Shin SK, Kim YH, and Choi CY. Inhibition of APP intracellular domain (AICD) transcriptional activity via covalent conjugation with Nedd8. Biochem Biophys Res Commun 366: 976-981, 2008.
73. Li X, Zhao Q, Liao R, Sun P, and Wu X. The SCF(Skp2) ubiquitin ligase complex interacts with the human replication licensing factor Cdt1 and regulates Cdt1 degradation. J Biol Chem 278: 30854-30858, 2003.
74. Liakopoulos D, Doenges G, Matuschewski K, and Jentsch S. A novel protein modification pathway related to the ubiquitin system. EMBO J 17: 2208-2214, 1998.
75. Liao H, Liu XJ, Blank JL, Bouck DC, Bernard H, Garcia K, and Lightcap ES. Quantitative proteomic analysis of cellular protein modulation upon inhibition of the NEDD8-activating enzyme by MLN4924. Mol Cell Proteomics 10: M111.009183, 2011.
76. Lin HK, Chen Z, Wang G, Nardella C, Lee SW, Chan CH, Yang WL, Wang J, Egia A, Nakayama KI, Cordon-Cardo C, Teruya-Feldstein J, and Pandolfi PP. Skp2 targeting suppresses tumorigenesis by Arf-p53-independent cellular senescence. Nature 464: 374-379, 2010.
77. Lin JJ, Milhollen MA, Smith PG, Narayanan U, and Dutta A. NEDD8-targeting drug MLN4924 elicits DNA rereplication by stabilizing Cdt1 in S phase, triggering checkpoint activation, apoptosis, and senescence in cancer cells. Cancer Res 70: 10310-10320, 2010.
78. Liu J, Furukawa M, Matsumoto T, and Xiong Y. NEDD8 modification of CUL1 dissociates p120CAND1, an inhibitor of CUL1-SKP1 binding and SCF ligases. Mol Cell 10: 1511-1518, 2002.
79. Lo S-C and Hannink M. CAND1-Mediated substrate adaptor recycling is required for efficient repression of Nrf2 by Keap1. Mol Cell Biol 26: 1235-1244, 2006.
80. Loftus SJ, Liu G, Carr SM, Munro S, and La Thangue NB. NEDDylation regulates E2F-1-dependent transcription. EMBO Rep 13: 811-818, 2012.
81. Lohrum MA, Ludwig RL, Kubbutat MH, Hanlon M, and Vousden KH. Regulation of HDM2 activity by the ribosomal protein L11. Cancer Cell 3: 577-587, 2003.
82. Luo Z, Yu G, Lee HW, Li L, Wang L, Yang D, Pan Y, Ding C, Qian J, Wu L, Chu Y, Yi J, Wang X, Sun Y, Jeong LS, Liu J, and Jia L. The Nedd8-activating enzyme inhibitor MLN4924 induces autophagy and apoptosis to suppress liver cancer cell growth. Cancer Res 72: 3360-3371, 2012.
83. Lyapina S, Cope G, Shevchenko A, Serino G, Tsuge T, Zhou C, Wolf DA, Wei N, Shevchenko A, and Deshaies RJ. Promotion of NEDD8-CUL1 conjugate cleavage by COP9 signalosome. Science 292: 1382-1385, 2001.
84. Ma T, Chen Y, Zhang F, Yang C-Y, Wang S, and Yu X. RNF111-Dependent neddylation activates DNA damageinduced ubiquitination. Mol Cell 49: 897-907, 2013.
85. Mackintosh C, Garcia-Dominguez DJ, Ordonez JL, Ginel-Picardo A, Smith PG, Sacristan MP, and de Alava E. WEE1 accumulation and deregulation of S-phase proteins mediate MLN4924 potent inhibitory effect on Ewing sarcoma cells. Oncogene 32: 1441-1451, 2013.
86. Mann M. Functional and quantitative proteomics using SILAC. Nat Rev Mol Cell Biol 7: 952-958, 2006.
87. Martin D, Salinas M, Fujita N, Tsuruo T, and Cuadrado A. Ceramide and reactive oxygen species generated by H2O2 induce caspase-3-independent degradation of Akt/protein kinase B. J Biol Chem 277: 42943-42952, 2002.
88. McMillin DW, Jacobs HM, Delmore JE, Buon L, Hunter ZR, Monrose V, Yu J, Smith PG, Richardson PG, Anderson KC, Treon SP, Kung AL, and Mitsiades CS. Molecular and cellular effects of NEDD8-activating enzyme inhibition in myeloma. Mol Cancer Ther 11: 942-951, 2012.
89. Mendoza HM, Shen LN, Botting C, Lewis A, Chen J, Ink B, and Hay RT. NEDP1, a highly conserved cysteine protease that deNEDDylates Cullins. J Biol Chem 278: 25637-25643, 2003.
90. Meyer-Schaller N, Chou Y-C, Sumara I, Martin DDO, Kurz T, Katheder N, Hofmann K, Berthiaume LG, Sicheri F, and Peter M. The human Dcn1-like protein DCNL3 promotes Cul3 neddylation at membranes. Proc Natl Acad Sci USA 106: 12365-12370, 2009.
91. Milhollen MA, Narayanan U, Soucy TA, Veiby PO, Smith PG, and Amidon B. Inhibition of NEDD8-activating enzyme induces rereplication and apoptosis in human tumor cells consistent with deregulating CDT1 turnover. Cancer Res 71: 3042-3051, 2011.
92. Milhollen MA, Thomas MP, Narayanan U, Traove T, Riceberg J, Amidon BS, Bence NF, Bolen JB, Brownell J, Dick LR, Loke HK, McDonald AA, Ma J, Manfredi MG, Sells TB, Sintchak MD, Yang X, Xu Q, Koenig EM, Gavin JM, and Smith PG. Treatment-emergent mutations in NAEbeta confer resistance to the NEDD8-activating enzyme inhibitor MLN4924. Cancer Cell 21: 388-401, 2012.
93. Mihollen MA, Traore T, Adams-Duffy J, Thomas MP, Berger AJ, Dang L, Dick LR, Garnsey JJ, Koenig E, Langston SP, Manfredi M, Narayanan U, Rolfe M, Staudt LM, Soucy TA, Yu J, Zhang J, Bolen JB, and Smith PG. MLN4924, a NEDD8-activating enzyme inhibitor, is active in diffuse large B-cell lymphoma models: rationale for treatment of NF-{kappa}B-dependent lymphoma. Blood 116: 1515-1523, 2010.
94. Mizushima N, Yoshimori T, and Levine B. Methods in mammalian autophagy research. Cell 140: 313-326, 2010.
95. Morgan MA, Parsels LA, Maybaum J, and Lawrence TS. Improving gemcitabine-mediated radiosensitization using molecularly targeted therapy: a review. Clin Cancer Res 14: 6744-6750, 2008.
96. Mori F, Nishie M, Piao YS, Kito K, Kamitani T, Takahashi H, and Wakabayashi K. Accumulation of NEDD8 in neuronal and glial inclusions of neurodegenerative disorders. Neuropathol Appl Neurobiol 31: 53-61, 2005.
97. Nagano T, Hashimoto T, Nakashima A, Kikkawa U, and Kamada S. X-linked inhibitor of apoptosis protein mediates neddylation by itself but does not function as a NEDD8-E3 ligase for caspase-7. FEBS Lett 586: 1612-1616, 2012.
98. Nawrocki ST, Griffin P, Kelly KR, and Carew JS. MLN4924: a novel first-in-class inhibitor of NEDD8-activating enzyme for cancer therapy. Expert Opin Investig Drugs 21: 1563-1573, 2012.
99. Nawrocki ST, Kelly KR, Smith PG, Espitia CM, Possemato A, Beausoleil SA, Milhollen M, Blakemore S, Thomas M, Berger A, and Carew JS. Disrupting protein NEDDylation with MLN4924 is a novel strategy to target cisplatin resistance in ovarian cancer. Clin Cancer Res 19: 3577-3590, 2013.
100. Noguchi K, Okumura F, Takahashi N, Kataoka A, Kamiyama T, Todo S, and Hatakeyama S. TRIM40 promotes neddylation of IKKc and is downregulated in gastrointestinal cancers. Carcinogenesis 32: 995-1004, 2011.
101. Noh EH, Hwang HS, Hwang HS, Min B, Im E, and Chung KC. Covalent NEDD8 conjugation increases RCAN1 protein stability and potentiates its inhibitory action on calcineurin. PLos One 7: e48315, 2012.
102. Ong S-E. The expanding field of SILAC. Anal Bioanal Chem 404: 967-976, 2012.
103. Ong S-E, Blagoev B, Kratchmarova I, Kristensen DB, Steen H, Pandey A, and Mann M. Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol Cell Proteomics 1: 376-386, 2002.
104. Ong SE and Mann M. A practical recipe for stable isotope labeling by amino acids in cell culture (SILAC). Nat Protoc 1: 2650-2660, 2006.
105. Orlowski RZ and Kuhn DJ. Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 14: 1649-1657, 2008.
106. Osaka F, Saeki M, Katayama S, Aida N, Toh-e A, Kominami K-i, Toda T, Suzuki T, Chiba T, Tanaka K, and Kato S. Covalent modifier NEDD8 is essential for SCF ubiquitin-ligase in fission yeast. EMBO J 19: 3475-3484, 2000.
107. Ou C-Y, Lin Y-F, Chen Y-J, and Chien C-T. Distinct protein degradation mechanisms mediated by Cul1 and Cul3 controlling Ci stability in Drosophila eye development. Genes Dev 16: 2403-2414, 2002.
108. Oved S, Mosesson Y, Zwang Y, Santonico E, Shtiegman K, Marmor MD, Kochupurakkal BS, Katz M, Lavi S, Cesareni G, and Yarden Y. Conjugation to Nedd8 instigates ubiquitylation and down-regulation of activated receptor tyrosine kinases. J Biol Chem 281: 21640-21651, 2006.
109. Pan Z-Q, Kentsis A, Dias DC, Yamoah K, and Wu K. Nedd8 on cullin: building an expressway to protein destruction. Oncogene 23: 1985-1997, 2004.
110. Peterson TR, Laplante M, Thoreen CC, Sancak Y, Kang SA, Kuehl WM, Gray NS, and Sabatini DM. DEPTOR is an mTOR inhibitor frequently overexpressed in multiple myeloma cells and required for their survival. Cell 137: 873-886, 2009.
111. Pozo JCd, Timpte C, Tan S, Callis J, and Estelle M. The ubiquitin-related protein RUB1 and auxin response in arabidopsis. Science 280: 1760-1763, 1998.
112. Rabut G, Le Dez G, Verma R, Makhnevych T, Knebel A, Kurz T, Boone C, Deshaies Raymond J, and Peter M. The TFIIH subunit Tfb3 regulates cullin neddylation. Mol Cell 43: 488-495, 2011.
113. Rabut G and Peter M. Function and regulation of protein neddylation. 'Protein modifications: beyond the usual suspects' review series. EMBO Rep 9: 969-976, 2008.
114. Rada P, Rojo AI, Chowdhry S, McMahon M, Hayes JD, and Cuadrado A. SCF/{beta}-TrCP promotes glycogen synthase kinase 3-dependent degradation of the Nrf2 transcription factor in a Keap1-independent manner. Mol Cell Biol 31: 1121-1133, 2011.
115. Rada P, Rojo AI, Evrard-Todeschi N, Innamorato NG, Cotte A, Jaworski T, Tobon-Velasco JC, Devijver H, Garcia-Mayoral MF, Van Leuven F, Hayes JD, Bertho G, and Cuadrado A. Structural and functional characterization of Nrf2 degradation by the glycogen synthase kinase 3/beta-TrCP axis. Mol Cell Biol 32: 3486-3499, 2012.
116. Reverter D, Wu K, Erdene TG, Pan Z-Q, Wilkinson KD, and Lima CD. Structure of a complex between Nedd8 and the Ulp/Senp protease family member Den1. J Mol Biol 345: 141-151, 2005.
117. Rushmore TH, Morton MR, and Pickett CB. The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity. J Biol Chem 266: 11632-11639, 1991.
118. Ryu J-H, Li S-H, Park H-S, Park J-W, Lee B, and Chun YS. Hypoxia-inducible factor a subunit stabilization by NEDD8 conjugation is reactive oxygen species-dependent. J Biol Chem 286: 6963-6970, 2011.
119. Saha A and Deshaies RJ. Multimodal activation of the ubiquitin ligase SCF by Nedd8 conjugation. Mol Cell 32: 21-31, 2008.
120. Salon C, Brambilla E, Brambilla C, Lantuejoul S, Gazzeri S, and Eymin B. Altered pattern of Cul-1 protein expression and neddylation in human lung tumours: relationships with CAND1 and cyclin E protein levels. J Pathol 213: 303-310, 2007.
121. Scott DC, Monda JK, Bennett EJ, Harper JW, and Schulman BA. N-terminal acetylation acts as an avidity enhancer within an interconnected multiprotein complex. Science 334: 674-678, 2011.
122. Shen L-n, Liu H, Dong C, Xirodimas D, Naismith JH, and Hay RT. Structural basis of NEDD8 ubiquitin discrimination by the deNEDDylating enzyme NEDP1. EMBO J 24: 1341-1351, 2005.
123. Singh RK, Iyappan S, and Scheffner M. Heterooligomerization with MdmX rescues the ubiquitin/Nedd8 ligase activity of RING finger mutants of Mdm2. J Biol Chem 282: 10901-10907, 2007.
124. Skaar JR and Pagano M. Control of cell growth by the SCF and APC/C ubiquitin ligases. Curr Opin Cell Biol 21: 816-824, 2009.
125. Smith MA, Maris JM, Gorlick R, Kolb EA, Lock R, Carol H, Keir ST, Reynolds CP, Kang MH, Morton CL, Wu J, Smith PG, Yu J, and Houghton PJ. Initial testing of the investigational NEDD8-activating enzyme inhibitor MLN4924 by the pediatric preclinical testing program. Pediatr Blood Cancer 59: 246-253, 2012.
126. Soucy TA, Dick LR, Smith PG, Milhollen MA, and Brownell JE. The NEDD8 conjugation pathway and its relevance in cancer biology and therapy. Genes Cancer 1: 708-716, 2010.
127. Soucy TA, Smith PG, Milhollen MA, Berger AJ, Gavin JM, Adhikari S, Brownell JE, Burke KE, Cardin DP, Critchley S, Cullis CA, Doucette A, Garnsey JJ, Gaulin JL, Gershman RE, Lublinsky AR, McDonald A, Mizutani H, Narayanan U, Olhava EJ, Peluso S, Rezaei M, Sintchak MD, Talreja T, Thomas MP, Traore T, Vyskocil S, Weatherhead GS, Yu J, Zhang J, Dick LR, Claiborne CF, Rolfe M, Bolen JB, and Langston SP. An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer. Nature 458: 732-736, 2009.
128. Soucy TA, Smith PG, and Rolfe M. Targeting NEDD8-activated cullin-RING ligases for the treatment of cancer. Clin Cancer Res 15: 3912-3916, 2009.
129. Sporn MB and Liby KT. NRF2 and cancer: the good, the bad and the importance of context. Nat Rev Cancer 12: 564-571, 2012.
130. Stickle NH, Chung J, Klco JM, Hill RP, Kaelin WG, and Ohh M. pVHL Modification by NEDD8 is required for fibronectin matrix assembly and suppression of tumor development. Mol Cell Biol 24: 3251-3261, 2004.
131. Sun Y. Free radicals, antioxidant enzymes, and carcinogenesis. Free Radic Biol Med 8: 583-599, 1990.
132. Sun Y and Li H. Functional characterization of SAG/RBX2/ROC2/RNF7, an antioxidant protein and an E3 ubiquitin ligase. Protein Cell 4: 103-116, 2013.
133. Sundqvist A, Liu G, Mirsaliotis A, and Xirodimas DP. Regulation of nucleolar signalling to p53 through NEDDylation of L11. EMBO Rep 10: 1132-1139, 2009.
134. Swords RT, Kelly KR, Smith PG, Garnsey JJ, Mahalingam D, Medina E, Oberheu K, Padmanabhan S, O'Dwyer M, Nawrocki ST, Giles FJ, and Carew JS. Inhibition of NEDD8-activating enzyme: a novel approach for the treatment of acute myeloid leukemia. Blood 115: 3796-3800, 2010.
135. Tan M, Li Y, Yang R, Xi N, and Sun Y. Inactivation of SAG E3 ubiquitin ligase blocks embryonic stem cell differentiation and sensitizes leukemia cells to retinoid acid. PLoS One 6: e27726, 2011.
136. Tan M, Zhao Y, Kim S-J, Liu M, Jia L, Saunders Thomas L, Zhu Y, and Sun Y. SAG/RBX2/ROC2 E3 ubiquitin ligase is essential for vascular and neural development by targeting NF1 for degradation. Dev Cell 21: 1062-1076, 2011.
137. Tateishi K, Omata M, Tanaka K, and Chiba T. The NEDD8 system is essential for cell cycle progression and morphogenetic pathway in mice. J Cell Biol 155: 571-580, 2001.
138. Tonks NK. Redox redux: revisiting PTPs and the control of cell signaling. Cell 121: 667-670, 2005.
139. Toth Julia I, Yang L, Dahl R, and Petroski Matthew D. A gatekeeper residue for NEDD8-activating enzyme inhibition by MLN4924. Cell Rep 1: 309-316, 2012.
140. Um JW, Han KA, Im E, Oh Y, Lee K, and Chung KC. Neddylation positively regulates the ubiquitin E3 ligase activity of parkin. J Neurosci Res 90: 1030-1042, 2012.
141. Villeneuve NF, Lau A, and Zhang DD. Regulation of the Nrf2-Keap1 antioxidant response by the ubiquitin proteasome system: an insight into cullin-ring ubiquitin ligases. Antioxid Redox Signal 13: 1699-1712, 2010.
142. Watson IR, Blanch A, Lin DCC, Ohh M, and Irwin MS. Mdm2-mediated NEDD8 modification of TAp73 regulates its transactivation function. J Biol Chem 281: 34096-34103, 2006.
143. Watson IR, Irwin MS, and Ohh M. NEDD8 pathways in cancer, Sine Quibus Non. Cancer Cell 19: 168-176, 2011.
144. Watson IR, Li BK, Roche O, Blanch A, Ohh M, and Irwin MS. Chemotherapy induces NEDP1-mediated destabilization of MDM2. Oncogene 29: 297-304, 2009.
145. Wei D, Li H, Yu J, Sebolt JT, Zhao L, Lawrence TS, Smith PG, Morgan MA, and Sun Y. Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor. Cancer Res 72: 282-293, 2012.
146. Wei N and Deng XW. The COP9 signalosome. Annu Rev Cell Dev Biol 19: 261-286, 2003.
147. Wei N, Serino G, and Deng XW. The COP9 signalosome: more than a protease. Trends Biochem Sci 33: 592-600, 2008.
148. Winston JT, Strack P, Beer-Romero P, Chu CY, Elledge SJ, and Harper JW. The SCFb-TRCP-ubiquitin ligase complex associates specifically with phosphorylated destruction motifs in IjBa and b-catenin and stimulates IjBa ubiquitination in vitro. Genes Dev 13: 270-283, 1999.
149. Wu K, Yamoah K, Dolios G, Gan-Erdene T, Tan P, Chen A, Lee CG, Wei N, Wilkinson KD, Wang R, and Pan ZQ. DEN1 is a dual function protease capable of processing the C terminus of Nedd8 and deconjugating hyperneddylated CUL1. J Biol Chem 278: 28882-28891, 2003.
150. Xirodimas DP, Saville MK, Bourdon J-C, Hay RT, and Lane DP. Mdm2-mediated NEDD8 conjugation of p53 inhibits its transcriptional activity. Cell 118: 83-97, 2004.
151. Xirodimas DP, Sundqvist A, Nakamura A, Shen L, Botting C, and Hay RT. Ribosomal proteins are targets for the NEDD8 pathway. EMBO Rep 9: 280-286, 2008.
152. Yamoah K, Oashi T, Sarikas A, Gazdoiu S, Osman R, and Pan Z-Q. Autoinhibitory regulation of SCF-mediated ubiquitination by human cullin 1's C-terminal tail. Proc Natl Acad Sci USA 105: 12230-12235, 2008.
153. Yang D, Li L, Liu H, Wu L, Luo Z, Li H, Zheng S, Gao H, Chu Y, Sun Y, Liu J, and Jia L. Induction of autophagy and senescence by knockdown of ROC1 E3 ubiquitin ligase to suppress the growth of liver cancer cells. Cell Death Differ 20: 235-247, 2013.
154. Yang D, Tan M, Wang G, and Sun Y. The p21-dependent radiosensitization of human breast cancer cells by MLN4924, an investigational inhibitor of NEDD8 activating enzyme. PLos One 7: e34079, 2012.
155. Yang D, Zhao Y, Liu J, Sun Y, and Jia L. Protective autophagy induced by RBX1/ROC1 knockdown or CRL inactivation via modulating the DEPTOR-MTOR axis. Autophagy 8: 1856-1858, 2012.
156. Yen H-CS, Xu Q, Chou DM, Zhao Z, and Elledge SJ. Global protein stability profiling in mammalian cells. Science 322: 918-923, 2008.
157. Yu Z-K, Gervais JLM, and Zhang H. Human CUL-1 associates with the SKP1/SKP2 complex and regulates p21CIP1/WAF1 and cyclin D proteins. Proc Natl Acad Sci USA 95: 11324-11329, 1998.
158. Zhang DD, Lo SC, Cross JV, Templeton DJ, and Hannink M. Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex. Mol Cell Biol 24: 10941-10953, 2004.
159. Zhang J, Bai D, Ma X, Guan J, and Zheng X. hCINAP is a novel regulator of ribosomal protein-HDM2-p53 pathway by controlling NEDDylation of ribosomal protein S14. Oncogene 33: 246-254, 2014.
160. Zhang Y, Wolf GW, Bhat K, Jin A, Allio T, Burkhart WA, and Xiong Y. Ribosomal protein L11 negatively regulates oncoprotein MDM2 and mediates a p53-dependent ribosomal-stress checkpoint pathway. Mol Cell Biol 23: 8902-8912, 2003.
161. Zhao L, Yue P, Lonial S, Khuri FR, and Sun SY. The NEDD8-activating enzyme inhibitor, MLN4924, cooperates with TRAIL to augment apoptosis through facilitating c-FLIP degradation in head and neck cancer cells. Mol Cancer Ther 10: 2415-2425, 2011.
162. Zhao Y and Sun Y. Targeting the mTOR-DEPTOR pathway by CRL E3 ubiquitin ligases: therapeutic application. Neoplasia (New York, NY) 14: 360-367, 2012.
163. Zhao Y and Sun Y. Cullin-RING ligases as attractive anticancer targets. Curr Pharm Des 19: 3215-3225, 2013.
164. Zhao Y, Xiong X, Jia L, and Sun Y. Targeting Cullin-RING ligases by MLN4924 induces autophagy via modulating the HIF1-REDD1-TSC1-mTORC1-DEPTOR axis. Cell Death Dis 3: e386, 2012.
165. Zhao Y, Xiong X, and Sun Y. DEPTOR, an mTOR inhibitor, is a physiological substrate of SCFbTrCP E3 ubiquitin ligase and regulates survival and autophagy. Mol Cell 44: 304-316, 2011.
166. Zheng J, Yang X, Harrell JM, Ryzhikov S, Shim E-H, Lykke-Andersen K, Wei N, Sun H, Kobayashi R, and Zhang H. CAND1 binds to unneddylated CUL1 and regulates the formation of SCF ubiquitin E3 ligase complex. Mol Cell 10: 1519-1526, 2002.
167. Zheng N, Schulman BA, Song LZ, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, Conaway RC, Conaway JW, Harper JW, and Pavletich NP. Structure of the Cul1-Rbx1-Skp1-F box(Skp2) SCF ubiquitin ligase complex. Nature 416: 703-709, 2002.
168. Zhou W, Wei W, and Sun Y. Genetically engineered mouse models for functional studies of SKP1-CUL1-Fbox-protein (SCF) E3 ubiquitin ligases. Cell Res 23: 599-619, 2013.
169. Zhou X, Hao Q, Liao J, Zhang Q, and Lu H. Ribosomal protein S14 unties the MDM2-p53 loop upon ribosomal stress. Oncogene 32: 388-396, 2013.
170. Zuo W, Huang F, Chiang YJ, Li M, Du J, Ding Y, Zhang T, Lee Hyuk W, Jeong Lak S, Chen Y, Deng H, Feng X-H, Luo S, Gao C, and Chen Y-G. c-Cbl-mediated neddylation antagonizes ubiquitination and degradation of the TGF-b Type II Receptor. Mol Cell 49: 499-510, 2013.